Autologous stem cell mobilization in the age of plerixafor
Plerixafor is a potent stem cell mobilizing agent whose cost is prohibitive for routine use. In 277 consecutive patients, the addition of rescue plerixafor during suboptimal G-CSF mobilization or after prior failure of chemotherapy plus G-CSF, was associated with successful mobilization in 97.5% of patients with target collections achieved in 60% of lymphoma and 72% of myeloma patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Dennis L. Cooper, Erin Medoff, Natalie Patel, Julie Baker, Kathryn Pratt, Francine Foss, Stuart E. Seropian, Sarah Perreault, Yanyun Wu Tags: Original Study Source Type: research
More News: Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Study